patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug
CYLTEZO
Marketedupdated 2mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
all catalysts(12)
approval · 12
Aug 25, 2017
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Sep 13, 2019
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Oct 15, 2021
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Mar 18, 2022
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Oct 3, 2022
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Mar 22, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
May 18, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Jun 30, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Jul 19, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Apr 30, 2024
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
May 20, 2025
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Oct 16, 2025
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that